OTARMENI
STN: 125874
Proper Name: lunsotogene parvec-cwha
Tradename: OTARMENI
Manufacturer: Regeneron Pharmaceuticals, Inc.
Indications:
- For the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (HL; any frequency >90 dB) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.